Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
12,086.70114.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Glenmark gets final nod from USFDA for angina treatment drug

The product is a generic version of Gilead Sciences Inc's Ranexa extended-release tablets in the same strengths.

PTI|
Jul 09, 2019, 02.05 PM IST
0Comments
BCCL
pharma-BCCL2
Ranolazine is used to treat chronic angina.
NEW DELHI: Glenmark Pharmaceuticals Tuesday said it has received final nod from the US health regulator for its Ranolazine extended-release tablets used for treatment of chronic angina.

Glenmark Pharmaceuticals Inc has been granted final approval by the United States Food & Drug Administration (USFDA) for Ranolazine extended-release tablets in the strengths of 500 mg and 1,000 mg, the company said in a statement.

The product is a generic version of Gilead Sciences Inc's Ranexa extended-release tablets in the same strengths, it added.

According to IQVIA sales data for the 12-month period ended May 2019, Ranexa extended-release tablets, 500 mg and 1,000 mg market (which includes brand and all available therapeutic equivalents) achieved annual sales of around USD 929 million, Glenmark said.

The company's current portfolio consists of 158 products authorised for distribution in the US marketplace and 57 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.

Ranolazine is used to treat chronic angina.

Shares of Glenmark Pharmaceuticals were trading at Rs 448.25 per scrip on BSE, up 2.63 per cent from the previous close.

Also Read

Aurobindo Pharma tanks on USFDA observations

Aurobindo Pharma under USFDA scrutiny

Indoco Remedies receives EIR from USFDA

Alembic Pharma gets USFDA nod for Desonide Ointment

Lupin gets EIR from USFDA for Nagpur facility

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.

Other useful Links


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service